Bloomberg the Company

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Sunesis Pharmaceuticals Inc

+ Add to Watchlist


2.016 EUR 0.052 2.51%

As of 15:57:13 ET on 01/28/2015.

Snapshot for Sunesis Pharmaceuticals Inc (RYIN)

Open: 2.060 Day's Range: 1.994 - 2.061 Volume: 0
Previous Close: 2.068 52wk Range: 0.778 - 6.468 1-Yr Rtn: -38.16%

Stock Chart for RYIN

No chart data available.
  • RYIN:GR 2.060
  • 1D
  • 1M
  • 1Y
Interactive RYIN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for RYIN

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2014) -0.8450
Est. PEG Ratio -
Market Cap (M EUR) 124.64
Shares Outstanding (M) 61.95
30 Day Average Volume 899
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/06/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for RYIN

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for RYIN

Sunesis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for oncology, inflammatory diseases and other unmet medical needs. The company is advancing two proprietary oncology product candidates intended for the treatment of cancer.

Daniel N Swisher JrPresident/CEOAdam R CraigExec VP/Chief Medical Officer
Joseph I Depinto "Joe"Exec VP/Chief Commercial OfcrEric H BjerkholtExec VP:Finance/CFO/Secy
More Company Profile & Key Executives for RYIN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil